GS 1590

Drug Profile

GS 1590

Latest Information Update: 27 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon; LEO Pharma
  • Developer LEO Pharma
  • Class Neuroprotectants; Vitamins
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Nerve growth factor stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 23 Aug 2002 Discontinued - Preclinical for Neurological disorders in Denmark (unspecified route)
  • 25 Jul 2001 This compound is still in active development
  • 25 Aug 1999 Preclinical development for Neurological disorders in Denmark (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top